Remdesivir for the Treatment of Covid-19 - Final Report.N Engl J Med. 2020 11 05; 383(19):1813-1826.NEJM
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.
We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.
A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%).
Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).
- Beigel JH
- Tomashek KM
- Dodd LE
- Mehta AK
- Zingman BS
- Kalil AC
- Hohmann E
- Chu HY
- Luetkemeyer A
- Kline S
- Lopez de Castilla D
- Finberg RW
- Dierberg K
- Tapson V
- Adenosine Monophosphate
- Administration, Intravenous
- Antiviral Agents
- Coronavirus Infections
- Double-Blind Method
- Extracorporeal Membrane Oxygenation
- Kaplan-Meier Estimate
- Middle Aged
- Oxygen Inhalation Therapy
- Pneumonia, Viral
- Respiration, Artificial
- Time Factors
- Young Adult
- COVID-19 Drug Treatment
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
- Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
- Compassionate Use of Remdesivir for Patients with Severe Covid-19.
- Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
- Audio Interview: New Data on Remdesivir in Covid-19.
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
- Antiviral treatment for COVID-19: the evidence supporting remdesivir.